Alcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand despite recent market underperformance. ALC demonstrates steady revenue growth, improved core EPS guidance, and a pipeline of innovative products targeting high-need clinical niches like glaucoma and macular disease. Balance sheet strength is evident with investment-grade ratings and the lowest D/E ratio among peers, reducing leverage risk and enhancing the risk profile.

GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.

CATHARINES, ONTARIO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Algoma Central Corporation (“Algoma”) (TSX:ALC) announced today that it has entered into an agreement to sell, on a bought deal basis to a syndicate of underwriters led by CIBC Capital Markets, $50,000,000 aggregate principal amount of 6.20% convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Public Offering”).

GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.

GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.

CRDO expands its AI connectivity portfolio with the 1.6T ZeroFlap Active Light Cable, offering lower power consumption, enhanced reliability and extended reach.

[url="]Credo Technology Group Holding Ltd[/url] (Credo) (NASDAQ: CRDO), an innovator in providing connectivity at scale through fast, reliable, and energy-effic

Algoma Central Co. (TSE: ALC - Get Free Report) passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of C$23.31 and traded as high as C$23.99. Algoma Central shares last traded at C$23.90, with a volume of 4,445 shares trading hands. Algoma Central Price Performance The